On March 15, the Launch Meeting of Phase II Clinical Trial of LN020, a new Class 1 anti-influenza drug independently developed by Luning Pharmaceutical Co., Ltd., as well as the National Researchers' Meeting, was grandly held in Chongqing.

The leading unit of this research project is the National Clinical Research Center for Respiratory Diseases - the First Affiliated Hospital of Guangzhou Medical University. Professor Ye Feng serves as the principal investigator (PI) of this research. More than 70 authoritative experts in the fields of respiratory medicine and clinical pharmacy from 25 top clinical research centers across the country (including the Guangdong Provincial Hospital of Traditional Chinese Medicine, Shandong Qianfoshan Hospital, Shengjing Hospital Affiliated to China Medical University and other important clinical research institutions) participated in the meeting. Relevant persons in charge such as Yan Zhigang, Chairman of Luning Pharmaceutical Co., Ltd., and Dr. Zhang Hailong, President of Jingyi Medicine, attended the meeting together.

At the meeting, Yan Zhigang, Chairman of Luning Pharmaceutical Co., Ltd., delivered a welcome speech first. He reviewed the innovative journey of the enterprise in the antiviral field and emphasized the determination for the strategic transformation from imitation to original innovation. Liu Yong, General Manager of the R&D Center, systematically explained the innovative strategic layout of LN020.

Professor Ye Feng pointed out in the keynote report, "The co-circulation of COVID-19 and influenza viruses has become a new normal in global public health. As an anti-influenza drug with a brand-new mechanism of action, the advancement of the Phase II clinical trial of LN020 marks a key breakthrough in the field of innovative antiviral drugs in China."

Dr. Huang Chao from Jingyi Medicine provided a technical interpretation of the Phase II clinical protocol of the project, and elaborated on the details of the innovative protocols such as the randomized double-blind controlled design and the dynamic monitoring of viral load. Under the chairmanship of Professor Ye Feng, researchers from various centers conducted in-depth discussions on key aspects such as the enrollment criteria, the evaluation indicators of therapeutic efficacy, and the standardization of laboratory tests.

Professor Ye Feng delivered a concluding speech for this seminar. He expressed his gratitude to all the experts for their suggestions and contributions to this seminar, and also conveyed his beautiful expectations for the vigorous development of China's pharmaceutical industry.

Next, with the support of expert teams from all parties and researchers across the country, Luning Pharmaceutical will promote the implementation of the LN020 clinical trial with higher efficiency and stricter standards. It will continuously meet the medication needs of patients, enabling them to use domestically produced drugs that are safe and reassuring at an early date, and contribute to the health and well-being of the people.